RYBREVANT FASPRO™ (amivantamab and hyaluronidase-lpuj) combination demonstrates 77% overall response rate in first-line treatment of patients with advanced head and neck cancer
Johnson & Johnson announced Phase 1b/2 OrigAMI-4 Cohort 5 results showing subcutaneous amivantamab (RYBREVANT FASPRO) plus pembrolizumab and carboplatin achieved a 77% confirmed overall response rate in first-line recurrent/metastatic HNSCC outside HPV-associated oropharyngeal cancer, with 14% complete responses. Responses were durable, with 65% ongoing at a median follow-up of 10.6 months and 77% of patients alive at one year; safety was consistent with the individual agents and no Grade 3+ administration-related reactions occurred.
Key figures
- Drug Name
- RYBREVANT FASPRO (amivantamab and hyaluronidase-lpuj)
- Phase Of Trial
- Phase 1b/2 (Cohort 5 of OrigAMI-4); pivotal Phase 3 OrigAMI-5 ongoing
- One year survival
- 77%
- Responses ongoing
- 65% at median follow-up of 10.6 months
- Efficacy population n
- 29
- Overall response rate
- 77%
- Partial response rate
- 64%
- Complete response rate
- 14%
- Hnscc non hpv cohort n
- 22
- Hpv associated opscc orr
- 29%
AI analysis
Red flags3 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.